1.
Therapie
; 68(2): 117-8, 2013.
Article
in English
| MEDLINE
| ID: mdl-23773353
Subject(s)
Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/therapeutic use , Flupenthixol/pharmacokinetics , Flupenthixol/therapeutic use , Schizophrenia/drug therapy , Schizophrenia/metabolism , Administration, Oral , Adult , Chronic Disease , Delayed-Action Preparations , Humans , Male , Schizophrenic Psychology
2.
Case Rep Med
; 2011: 191735, 2011.
Article
in English
| MEDLINE
| ID: mdl-21869891
ABSTRACT
We report the case of a 25-year-old women suffering from major depression who was treated with citalopram for several weeks with doses between 20 mg and 60 mg. She gradually developed marked mydriasis within 2 months after treatment and subsequently neuritis nervi optici. Moreover, abrupt galactorrhea occurred after 2 months of treatment. All neuro-ophthalmological, neurophysiological, clinical laboratory, and neuroradiological diagnostic efforts did not reveal an underlying organic pathophysiology. The ocular symptoms disappeared rapidly after the discontinuation of citalopram and pulse therapy with methyl-prednisolone. However, galactorrhea persisted for a few weeks necessitating treatment with bromocriptine.